Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. develops clinical-stage medicines for oncology and other areas of unmet medical need. Its recurring news centers on (Z)-endoxifen, the company's lead product candidate, including breast cancer research, mammographic breast density data, and expansion into rare disease indications such as Duchenne muscular dystrophy and McCune-Albright Syndrome.
Company updates also cover FDA orphan and rare pediatric disease designations, clinical and preclinical data presentations, peer-reviewed publications, intellectual property developments, leadership additions, financial results, and capital-allocation commentary tied to Atossa's development strategy.
Atossa Therapeutics (Nasdaq: ATOS) reported successful in vitro results for its COVID-19 drug candidate, AT-H201, demonstrating potent inhibition of SARS-CoV-2 infectivity in VERO cells. The study showed AT-H201 as the first submicromolar inhibitor identified, surpassing the potency of remdesivir by four times and hydroxychloroquine by twenty times. Dr. Steven Quay, CEO, expressed optimism for further clinical development. However, the company warns that these initial results do not guarantee success in human trials, with additional safety and efficacy studies necessary before commercialization.
Atossa Therapeutics (ATOS) reported its Q1 2020 financial results, revealing no sustainable revenue and total operating expenses of approximately $2.94 million, down 28% from Q1 2019. Key developments include the launch of the COVID-19 HOPE program to test AT-H201, aiming to improve lung function in COVID-19 patients. Positive interim results from the Phase 2 study of oral Endoxifen indicated a 74% reduction in tumor cell proliferation. The company is planning further clinical trials, with approximately $9.4 million in cash as of March 31, 2020.
Atossa Therapeutics (NASDAQ: ATOS) announced positive interim results from its Phase 2 study of oral Endoxifen for breast cancer, reporting a statistically significant 74% reduction in tumor cell proliferation (p = 0.031) over 22 days. All six patients showed a decrease in Ki-67, a key proliferation marker, with levels dropping below 25%. The study, conducted in Australia, aims to enroll 25 patients, and successful results may lead to a Phase 3 study. There were no safety concerns noted, and patients reported fewer side effects compared to traditional therapies.